Sensei Biotherapeutics (NASDAQ:SNSE) Upgraded to Hold at Zacks Research

Zacks Research upgraded shares of Sensei Biotherapeutics (NASDAQ:SNSE) to a hold rating in a research report sent to investors on Tuesday morning,Zacks.com reports.

A number of other equities research analysts have also recently weighed in on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Sensei Biotherapeutics in a research note on Monday, December 29th. Leerink Partners started coverage on shares of Sensei Biotherapeutics in a research report on Monday. They set an “outperform” rating and a $50.00 price objective for the company. Finally, Wall Street Zen upgraded shares of Sensei Biotherapeutics to a “hold” rating in a report on Saturday, December 27th. One analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $40.00.

Sensei Biotherapeutics Trading Up 4.2%

NASDAQ SNSE opened at $31.64 on Tuesday. The stock has a fifty day simple moving average of $28.78 and a 200-day simple moving average of $16.43. The stock has a market cap of $42.40 million, a PE ratio of -1.90 and a beta of -0.10. Sensei Biotherapeutics has a twelve month low of $5.25 and a twelve month high of $36.76.

Sensei Biotherapeutics (NASDAQ:SNSE) last issued its quarterly earnings data on Monday, March 30th. The company reported ($3.74) earnings per share (EPS) for the quarter, beating the consensus estimate of ($4.81) by $1.07. Research analysts predict that Sensei Biotherapeutics will post -2.77 EPS for the current year.

Institutional Trading of Sensei Biotherapeutics

A hedge fund recently raised its stake in Sensei Biotherapeutics stock. Renaissance Technologies LLC lifted its stake in Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) by 10.6% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 11,516 shares of the company’s stock after purchasing an additional 1,100 shares during the period. Renaissance Technologies LLC owned about 0.91% of Sensei Biotherapeutics worth $123,000 at the end of the most recent quarter. Institutional investors own 10.50% of the company’s stock.

Sensei Biotherapeutics Company Profile

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of immunotherapies that harness both the innate and adaptive arms of the immune system to treat cancer and autoimmune diseases. Utilizing proprietary antibody engineering and biologics platforms, Sensei aims to develop next-generation checkpoint modulators and immune agonists designed to overcome the limitations of current therapies.

The company’s lead programs include SIS-100, a first-in-class antagonist targeting Siglec-15 being evaluated in solid tumors to relieve immune suppression in the tumor microenvironment, and SIS-101, an antibody directed against CD39 intended to restore T-cell function by modulating adenosine signaling pathways.